Work

Mechanisms and anatomical risk factors of pneumothorax after Bevacizumab use: A case report

Year: 2020

Type: article

Abstract: BACKGROUND: Bevacizumab is an antiangiogenic agent, and that synergizes with chemotherapeutic drugs. When used in combination therapies, Bevacizumab is associated with adverse events such as hemorrhage, gastrointestinal perforation, delayed wound healing, and pneumothorax. However, the molecular mechanisms underlying these adverse events are not fully understood. CASE SUMMARY: day of drainage, the patient was discharged from our hospital on recovery. Recurrence of pneumothorax was not reported, and continuation of chemotherapy was made possible by changing the regimen. CONCLUSION: Patients with lung metastases surrounding the bronchi and on the pleura should be monitored for pneumothorax by Bevacizumab-containing chemotherapies.

Source: World Journal of Clinical Oncology

DOI: 10.5306/wjco.v11.i7.504

Authors: Yuri Ozaki1, Akiyo Yoshimura, Masataka Sawaki, Masaya Hattori, Naomi Gondo, Haruru Kotani, Yayoi Adachi, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuka Endo, Kazuki Nozawa, Shoko Sakamoto, Hiroji Iwata

Institutions: Aichi Cancer Center, Aichi Cancer Center Hospital

Language: English

Topic: Pleural and Pulmonary Diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W3045313758

FWCI: 0.464

Cites: 14

Cited by: 5

Related to: 10